Dementia Drugs Market Business still promises 8.4% CAGR by 2026 | Coherent Market Insights
SEATTLE, March 29, 2021, (PHARMIWEB) — Dementia Drugs Market – Insights
Dementia is an overall term for diseases and conditions characterized by decline in memory or other thinking skills. The most common form of dementia is Alzheimer’s disease that accounts for over 60% of all cases of dementia and generally impacts people aged 65 years or older. A major cause of dementia is genetic mutation that leads to accumulation of a protein called beta amyloid in the spaces between nerve cells. The condition has no cure. However, there are several therapies that aid in reducing the symptoms of the condition. Several institutes and research organizations are focused on conducting research to develop novel and effective therapies focused on the influence of beta-amyloid in the treatment of dementia.
The global dementia drugs market estimated to be valued at US$ 13,900.0 million in 2017 and is expected to witness a CAGR of 8.4% over the forecast period (2018–2026).
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1664
Figure 1. Global Dementia Drugs Market Value (US$ Mn) Forecast and Absolute $ Opportunity (US$ Mn)
Source: Coherent Market Insights Analysis (2018)
Increasing development of novel drugs for the treatment of dementia is expected to boost the market growth
Increasing number of drugs in the pipeline for the treatment of dementia that are expected to be launched in 2020-2022 is expected to boost the market growth. For instance, according to the study published by Translational Research and Clinical Intervention, in September 2017, 105 new drugs are in the pipeline, out of which 25 are in phase one, 52 in phase two, and 28 are in phase three. These new therapies use novel approaches such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor antagonist.
Moreover, key players in the market are focused on adopting collaboration strategies to expand their product portfolio, which is also expected to boost the market growth. For instance, in November 2017, Novartis and Amgen, along with the Banner Alzheimer’s Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer’s disease.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://bit.ly/2QR3GbH
However, failure of investigational candidates in late stage is expected to be hinder the market growth. For instance, in February 2017, an external data monitoring committee warned that Merck & Co., Inc. terminated study of Alzheimer’s candidate verubecestat due to potential failure in a Phase II/III study.
Increasing prevalence of Alzheimer’s disease is expected to boost growth of the dementia drugs market. For instance, according to World Alzheimer Report in 2016, around 46.5 million people were suffering from Alzheimer’s disease, the number for which is projected to reach 50 million by 2017. Increasing geriatric population is also expected to contribute to growing cases of Alzheimer’s disease, thereby propelling the market growth. For instance, according to World Population Prospects (WPP) published by United Nations in 2017, around 962 million people aged 60 years and above were recorded, which accounted for 13% of the global population. The number is projected to reach 1.4 billion by 2030, exhibiting annual growth rate of 3%. Europe accounted for the largest geriatric population (25% of population) in 2017, whereas Asia Pacific recorded a geriatric population of 547 million in 2017 and is projected to reach 900 million by 2025. Therefore, these regions demonstrate lucrative growth opportunities for the market players.
Global Dementia Drugs Market Regional Outlook – Growing Integration of Healthcare and IT to boost demand in emerging economies
On the basis of region, the global dementia drugs market can be segmented into six major regional markets: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account for the largest market share, owing to increasing drug approvals in the region and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in the near future, owing to growing geriatric population and Alzheimer’s disease cases, typically in China and India. For instance, according to Alzheimer’s Disease International Association, in 2015, East Asia recorded the maximum number of people living with dementia (9.8 million), followed by Western Europe (7.4 million).
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/dementia-drugs-market-to-surpass-us-284711-million-by-2026-874
Key players in the market are adopting various growth strategies such collaboration, acquisition, and product portfolio expansion to gain competitive edge in the market. For instance, in 2016, Teva Pharmaceutical Industries Ltd. acquired Actavis Generics from Allergan for around US$ 40 billion, which also includes the Alzheimer’s portfolio of Actavis Generics. This acquisition boosted revenue of Teva in its fourth quarter of 2016 and first quarter of 2017. Furthermore, Genentech and AC Immune are also jointly developing anti-amyloid beta antibody crenezumab, which started phase three clinical trial in 2017. The companies are developing anti-amyloid beta vaccine for Alzheimer’s disease treatment. Furthermore, AC Immune and Janssen Pharmaceutical are also co-developing vaccine for Alzheimer’s treatment.
Key players operating in the global dementia drugs market are Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Epidemiology
- Historical Overview
- Overview of Sub-classes of Drugs
- Revenue Potential of Drugs
- PORTER’S Five Forces
- PEST Analysis
- Market Dynamics
- Global Dementia Drugs Market, By Drug Class, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- MAO Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Glutamate Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Introduction
- Global Dementia Drugs Market, By Distribution Channel, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Introduction
- Global Dementia Drugs Market, By Regions, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2017–2026
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- Northern Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
